Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile. In all, 25 patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Morant, R, Bernhard, J, Dietrich, D, Gillessen, S, Bonomo, M, Borner, M, Bauer, J, Cerny, T, Rochlitz, C, Wernli, M, Gschwend, A, Hanselmann, S, Hering, F, Schmid, H-P
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2004
Teme:
Clinical
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409680/
https://ncbi.nlm.nih.gov/pubmed/15054447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601673
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki